International immunopharmacology · 2025
A study on the mechanism of action of Syringin in the treatment of type 2 diabetes by integrating metabolomics, network pharmacology, molecular docking technology and experimental validation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wan Chunlei, Sun Siyu, Du Yuqing, Han Yuxing, Li Xueying, Yang Yue, Cao Jianing, Miu Jin, Chen Peng, Zhang Yuexin, Liu Shaobo, Zhang Lei
Аннотация
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a metabolic disorder caused by insufficient insulin secretion from pancreatic beta cells or reduced insulin sensitivity in peripheral tissues. It has a high clinical incidence rate and can lead to various complications, significantly impacting patients' quality of life and lifespan. Syringin is a natural active compound, and studies have shown that it has certain therapeutic effects on diabetes, but its mechanism of action remains unclear.
METHODS: This study aims to investigate the therapeutic effects of Syringin on Type 2 diabetes mellitus (T2DM) and further explore its mechanism of action. Using a T2DM animal model induced by feeding a high-fat diet (HFD), high-sugar diet and intraperitoneal injection of streptozotocin (STZ), the study evaluated the therapeutic effects of the animal model and Syringin by measuring body weight, blood glucose levels, biochemical indicators, and histopathological changes in T2DM model mice. Additionally, metabolomics, network pharmacology,vitro experiments and using molecular docking techniques, we systematically analyzed the potential target of Syringin in treatingT2DM. Finally, the selected targets were further validated using Western blotting and ELISA techniques, thereby elucidating the mechanism of action of Syringin in treating T2DM.
RESULT: Pharmacodynamic results showed that Syringin can lower blood glucose levels and improve diabetic symptoms. Non-targeted metabolomics results indicated that there are 14 diabetes-related biomarkers, and Syringin may exert its therapeutic effects in T2DM by regulating the alpha-linolenic acid metabolic pathway and acting on PLA2G4B, PLAAT3, FADS2 targets to exert therapeutic effects in T2DM. Combined with network pharmacology, a total of 249 T2DM-related targets were screened. Network pharmacology and enrichment analysis, along with KEGG results, indicated that the core targets are AKT1, IL-6, and ALB. Molecular docking validation between Syringin and these targets demonstrated good binding affinity with all targets.In vitro cellular experiments confirm that Syringin inhibits apoptosis in high-glucose model HepG2 cells. Western blot and ELISA results demonstrate Syringin modulates the expression levels of PLA2G4B, PLAAT3, and FADS2 in the alpha-linolenic acid metabolic pathway, alongside target proteins AKT1, IL-6, and ALB, thereby improving T2DM.
CONCLUSION: Syringin has a good therapeutic effect on T2DM, and its potential mechanism of action has been discovered for the first time. It may treat type 2 diabetes by regulating the alpha-linolenic acid metabolic pathway and acting on its PLA2G4B, PLAAT3, and FADS2 targets, providing a solid foundation for the future clinical application of Syringin.
METHODS: This study aims to investigate the therapeutic effects of Syringin on Type 2 diabetes mellitus (T2DM) and further explore its mechanism of action. Using a T2DM animal model induced by feeding a high-fat diet (HFD), high-sugar diet and intraperitoneal injection of streptozotocin (STZ), the study evaluated the therapeutic effects of the animal model and Syringin by measuring body weight, blood glucose levels, biochemical indicators, and histopathological changes in T2DM model mice. Additionally, metabolomics, network pharmacology,vitro experiments and using molecular docking techniques, we systematically analyzed the potential target of Syringin in treatingT2DM. Finally, the selected targets were further validated using Western blotting and ELISA techniques, thereby elucidating the mechanism of action of Syringin in treating T2DM.
RESULT: Pharmacodynamic results showed that Syringin can lower blood glucose levels and improve diabetic symptoms. Non-targeted metabolomics results indicated that there are 14 diabetes-related biomarkers, and Syringin may exert its therapeutic effects in T2DM by regulating the alpha-linolenic acid metabolic pathway and acting on PLA2G4B, PLAAT3, FADS2 targets to exert therapeutic effects in T2DM. Combined with network pharmacology, a total of 249 T2DM-related targets were screened. Network pharmacology and enrichment analysis, along with KEGG results, indicated that the core targets are AKT1, IL-6, and ALB. Molecular docking validation between Syringin and these targets demonstrated good binding affinity with all targets.In vitro cellular experiments confirm that Syringin inhibits apoptosis in high-glucose model HepG2 cells. Western blot and ELISA results demonstrate Syringin modulates the expression levels of PLA2G4B, PLAAT3, and FADS2 in the alpha-linolenic acid metabolic pathway, alongside target proteins AKT1, IL-6, and ALB, thereby improving T2DM.
CONCLUSION: Syringin has a good therapeutic effect on T2DM, and its potential mechanism of action has been discovered for the first time. It may treat type 2 diabetes by regulating the alpha-linolenic acid metabolic pathway and acting on its PLA2G4B, PLAAT3, and FADS2 targets, providing a solid foundation for the future clinical application of Syringin.